Healthcare Strategies Group provides a unique blend of strategic advisory services and operational business development and general management support to the med-tech and pharmaceutical industries. The company’s advisory services are focused on commercial strategy development through to operational business development, market access and general management support.
The founder, Dr. Iain Miller, has extensive international experience, having split his career between the US and the EU. His client and broader experience base spans GE Healthcare, Biomerieux, J&J, Philips and the UK Government Technology Strategy Board, in addition to various SMEs and investor groups. In addition to his 20-year US experience, Dr. Miller has worked extensively in the UK and EU marketplace, including major market access policy projects with European thought leaders. He is also a founding Board member of the European Personalized Medicine Association and has been very active in the UK stratified medicine and broader med-tech ecosystems (Technology Strategy Board, Cancer Research UK, NICE DAP program, Academy of Medical Sciences). Iain also sits on the Oxford Bioscience Network Med-tech Advisory Board. The company is based in London, where Dr. Miller and his associates frequently provide market bridging services between the US and the EU, including on-the-ground UK / EU market development for US companies and US market development support for UK-based companies.
Please click here for more information on the services provided by Healthcare Strategies Group or here for more information on our clients and illustrative projects. Detailed information on the Founder and Team can be found here . Information on Company News and Events, including upcoming publications and links to our thought leadership articles, can be found here .
****** Latest News: Iain Miller, Founder of Healthcare Strategies Group to chair med-tech panel at BioTrinity, Europe’s leading biotechnology investment conference conference on May 13 in London. The panel, titled “Will companion Dx exist in 2020? The transition from single CDx paradigms to multi-omic testing”, will feature several international leaders from the pharmaceutical and diagnostic industries. Please click for more info.
****** Iain Miller interviewed in 2014 Wall Street Journal custom content paper “From Insight to Impact: Realizing the Potential of Innovation”, published at Davos. Please click for a full copy of the report.